{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:30Z","timestamp":1784700390437,"version":"3.55.0"},"reference-count":189,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recent advances in molecular and immunologic profiling have substantially refined the understanding of mycosis fungoides (MF) and S\u00e9zary syndrome (SS), the two most prominent subtypes of cutaneous T-cell lymphomas (CTCL). CTCL comprise a heterogeneous group of lymphoid malignancies characterized by clonal proliferation of malignant T-cell with cutaneous tropism. The pathogenesis of MF and SS appears to be driven by convergent oncogenic programs involving dysregulated JAK\/STAT, NF-\u03baB, PI3K\/AKT\/mTOR, and MAPK signaling, epigenetic reprogramming, apoptosis resistance, immune escape, and microenvironmental support. In parallel, altered surface phenotypes and chemokine receptor programs shape tissue tropism across skin, blood, and lymph nodes, while the tumor microenvironment promotes tumor persistence and Th2-skewed immune polarization. These insights have translated into novel targeted and immune-based therapies. This review summarizes current insights into the cell-intrinsic and microenvironmental biology of MF and SS and discusses emerging approaches aimed at achieving more durable and personalized disease control.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1899436","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:45Z","timestamp":1784699565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular and molecular aberrations generating new immunotherapeutic approaches in mycosis fungoides and S\u00e9zary syndrome: a comprehensive review of literature"],"prefix":"10.3389","volume":"17","author":[{"given":"Anna Sophia","family":"Flechtenmacher","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, University Medical Center Mannheim\/University of Heidelberg","place":["Mannheim, Germany"]},{"name":"Section of Immune Dermatology, Allergy and Cutaneous Lymphoma, Medical Faculty Mannheim, University of Heidelberg","place":["Mannheim, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Melchers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, University Medical Center Mannheim\/University of Heidelberg","place":["Mannheim, Germany"]},{"name":"Section of Immune Dermatology, Allergy and Cutaneous Lymphoma, Medical Faculty Mannheim, University of Heidelberg","place":["Mannheim, Germany"]},{"name":"Skin Cancer Unit, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Peter","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, University Medical Center Mannheim\/University of Heidelberg","place":["Mannheim, Germany"]},{"name":"Section of Immune Dermatology, Allergy and Cutaneous Lymphoma, Medical Faculty Mannheim, University of Heidelberg","place":["Mannheim, Germany"]},{"name":"Skin Cancer Unit, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]},{"name":"DKFZ-Hector Cancer Institute at the University Medical Center Mannheim","place":["Mannheim, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009655","article-title":"Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173171","article-title":"TP53 alterations in primary and secondary S\u00e9zary syndrome: A diagnostic tool for the assessment of Malignancy in patients with erythroderma","volume":"12","author":"Gros","year":"2017","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-6398","article-title":"Novel and highly recurrent chromosomal alterations in S\u00e9zary syndrome","volume":"68","author":"Vermeer","year":"2008","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182984","article-title":"Integrative mutational landscape of mycosis fungoides using a national genomics repository","volume":"17","author":"Saglimbeni","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.160","article-title":"Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides","volume":"57","author":"Bastidas Torres","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.4688","article-title":"JAK2 fusions in adult patients with mycosis fungoides and CD30 lymphoproliferative disorders","volume":"162","author":"Geller","year":"2026","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S\u00e9zary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(25)00322-9","article-title":"Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or S\u00e9zary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"13","author":"Stadler","year":"2026","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1926","article-title":"Linperlisib plus chidamide in relapsed or refractory cutaneous T-cell lymphoma: a nonrandomized clinical trial","volume":"161","author":"Pang","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","article-title":"Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors","volume":"32","author":"Qu","year":"2017","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.487","article-title":"MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma","volume":"135","author":"Sandoval","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4161\/15384101.2014.947759","article-title":"Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines","volume":"13","author":"Litvinov","year":"2014","journal-title":"Cell Cycle"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: Implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248298","article-title":"Ruxolitinib with resminostat exert synergistic antitumor effects in cutaneous T-cell lymphoma","volume":"16","author":"Karagianni","year":"2021","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001756","article-title":"JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL","volume":"4","author":"Yumeen","year":"2020","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-\u03baB and nuclear factor of activated T cells pathways","volume":"182","author":"P\u00e9rez","year":"2020","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1559494","article-title":"The NF-\u03baB signaling network in the life of T cells","volume":"16","author":"Daniels","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2536","article-title":"Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis","volume":"107","author":"Sors","year":"2006","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13701","article-title":"Molecular pathogenesis of cutaneous lymphomas","volume":"27","author":"Stadler","year":"2018","journal-title":"Exp Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.806799","article-title":"Bortezomib inhibits proteasomal degradation of I\u03baB\u03b1 and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma","volume":"55","author":"Bu","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694117","article-title":"Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-\u03baB","volume":"128","author":"Nicolay","year":"2016","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood.2022018669","article-title":"Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study","volume":"142","author":"Nicolay","year":"2023","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6825","article-title":"NF-\u03baB is a potential therapeutic target for histone deacetylase inhibitor-resistant cutaneous T-cell lymphoma","volume":"117","author":"Takahashi","year":"2026","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.027","article-title":"A comprehensive immunohistochemical approach of AKT\/mTOR pathway and p-STAT3 in mycosis fungoides","volume":"69","author":"Levidou","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0305-8","article-title":"Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K\/AKT\/mTORC1 pathway and its prognostic relevance","volume":"33","author":"Cristofoletti","year":"2019","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jid.2019.08.454","article-title":"Preclinical evidence for targeting PI3K\/mTOR signaling with dual-inhibitors as a therapeutic strategy against cutaneous T-cell lymphoma","volume":"140","author":"Bresin","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory T-cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-09-305128","article-title":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS\/RAF\/MEK signaling cascade","volume":"117","author":"Kiessling","year":"2011","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.2012.068510","article-title":"Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas","volume":"98","author":"Mart\u00edn-S\u00e1nchez","year":"2013","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.030","article-title":"Multi-kinase inhibitor with anti-p38\u03b3 activity in cutaneous T-cell lymphoma","volume":"138","author":"Zhang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14186","article-title":"Targeting the non-ATP-binding pocket of the MAP kinase p38\u03b3 mediates a novel mechanism of cytotoxicity in cutaneous T-cell lymphoma (CTCL)","volume":"595","author":"Zhang","year":"2021","journal-title":"FEBS Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/jamadermatol.2025.4081","article-title":"T-cell receptor clonotypes and aggressive subtypes in cutaneous T-cell lymphoma","volume":"162","author":"Crisan","year":"2026","journal-title":"JAMA Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-4631","article-title":"Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death","volume":"69","author":"Klemke","year":"2009","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400745","article-title":"Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk","volume":"11","author":"Fargnoli","year":"1997","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.364","article-title":"c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death","volume":"135","author":"Wu","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jid.2021.09.024","article-title":"PLC\u03b31\/PKC\u03b8 downstream signaling controls cutaneous T-cell lymphoma development and progression","volume":"142","author":"Garc\u00eda-D\u00edaz","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770982","article-title":"TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL","volume":"130","author":"Kremer","year":"2017","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.5bt1219-714r","article-title":"At the bedside: Profiling and treating patients with CXCR4-expressing cancers","volume":"109","author":"Martin","year":"2021","journal-title":"J Leukoc Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150585","article-title":"Inhibition of CXCR4 by LY2624587, a fully humanized anti-CXCR4 antibody induces apoptosis of hematologic Malignancies","volume":"11","author":"Peng","year":"2016","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264207","article-title":"C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma","volume":"64","author":"Buck","year":"2023","journal-title":"J Nucl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1996","article-title":"T-cell receptor signaling activates an ITK\/NF-\u03baB\/GATA-3 axis in T-cell lymphomas facilitating resistance to chemotherapy","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217602","article-title":"Interleukin-2-inducible T-cell kinase inhibition to block NF-\u03baB signaling exerts anti-tumor effects and enhances chemotherapy in NK\/T-cell lymphoma","volume":"618","author":"Cao","year":"2025","journal-title":"Cancer Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011916","article-title":"Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"key":"B60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-137782","article-title":"Cpi-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma","volume":"136","author":"Khodadoust","year":"2020","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"11301","DOI":"10.1182\/blood.v126.23.1451.1451","article-title":"Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data","volume":"7","author":"Gong","year":"2017","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.5.2714","article-title":"Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma","volume":"171","author":"Winter","year":"2003","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22113","article-title":"Identification of HLA class I dependent immunogenic peptides from clonotypic TCRbeta expressed in cutaneous T-cell lymphoma","volume":"119","author":"Zeng","year":"2006","journal-title":"Int J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(19980504)76:3<304::aid-ijc3>3.0.co;2-z","article-title":"Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor","volume":"76","author":"Berger","year":"1998","journal-title":"Int J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118681","article-title":"CAR-iNKT cells targeting clonal TCRV\u03b2 chains as a precise strategy to treat T cell lymphoma","volume":"14","author":"Rowan","year":"2023","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR \u03b2 chain-directed bispecific antibodies for the treatment of T cell cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell Malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00262-026-04302-5","article-title":"synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy","volume":"75","author":"Bhojnagarwala","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B70","article-title":"Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma","volume":"62","author":"Thirdborough","year":"2002","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(21)00637-7","article-title":"Improved S\u00e9zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in S\u00e9zary syndrome","volume":"138","author":"Najidh","year":"2021","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0710-0","article-title":"In situ depletion of CD4+ T cells in human skin by zanolimumab","volume":"298","author":"Villadsen","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01549","article-title":"Efficacy and safety of denileukin diftitox-cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"43","author":"Foss","year":"2025","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/his.14660","article-title":"Intraindividual variability of CD30 expression in mycosis fungoides -implications for diagnostic evaluation and therapy","volume":"81","author":"Mitteldorf","year":"2022","journal-title":"Histopathology"},{"key":"B77","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2004.01.003","article-title":"CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells","volume":"32","author":"H\u00fcbinger","year":"2004","journal-title":"Exp Hematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(26)00005-0","article-title":"Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell Malignancies","volume":"13","author":"Elliott","year":"2026","journal-title":"Lancet Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3424413","article-title":"CD38 expression by circulating and skin-infiltrating lymphocytes from Sezary syndrome patients: A flow cytometry and immunohistochemistry study","volume":"2022","author":"Quaglino","year":"2022","journal-title":"Dis Markers"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.12.009","article-title":"CD38- and Leu6-positive cells in dermal lesions of mycosis fungoides","volume":"106","author":"Liu","year":"1993","journal-title":"Chin Med J (Engl)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02551-4","article-title":"CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention","volume":"39","author":"Isabelle","year":"2025","journal-title":"Leukemia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study","volume":"14","author":"Huang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-06852-1","article-title":"Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed\/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi","author":"Ballerini","year":"2026","journal-title":"Ann Hematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215972","article-title":"Single-cell RNA sequencing unveils the communications between Malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma","volume":"551","author":"Du","year":"2022","journal-title":"Cancer Lett"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0622-6","article-title":"Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47","volume":"34","author":"Kamijo","year":"2020","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell Malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3444","article-title":"Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory S\u00e9zary syndrome: a systematic review","volume":"28","author":"Stewart","year":"2018","journal-title":"Eur J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell Malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34005","article-title":"Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma","volume":"128","author":"Leupin","year":"2022","journal-title":"Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005714","article-title":"Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models","volume":"6","author":"Wu","year":"2022","journal-title":"Blood Adv"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf001","article-title":"Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomas","volume":"192","author":"Costanza","year":"2025","journal-title":"Br J Dermatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15122","article-title":"The role of macrophage migration inhibitory factor family and CD74 in the pathogenesis of melanoma","volume":"33","author":"Tanese","year":"2024","journal-title":"Exp Dermatol"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18481","article-title":"Revisiting the initial diagnosis and blood staging of mycosis fungoides and S\u00e9zary syndrome with the KIR3DL2 marker","volume":"182","author":"Roelens","year":"2020","journal-title":"Br J Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3185","article-title":"Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with S\u00e9zary syndrome","volume":"23","author":"Hurabielle","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1016\/j.ejca.2025.115861","article-title":"Lacutamab in patients with relapsed and refractory S\u00e9zary syndrome: Long term follow-up from the TELLOMAK phase 2 trial","volume":"43","author":"Porcu","year":"2025","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00339","article-title":"New perspectives on the ligands and function of the killer cell immunoglobulin-like receptor KIR3DL2 in health and disease","volume":"3","author":"Shaw","year":"2012","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70062","article-title":"TNF production or TNFR2 expression characterize distinct states of regulatory T cells that cooperate in Treg expansion in cancer and chronic inflammation","volume":"55","author":"Tucci","year":"2025","journal-title":"Eur J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0292-9","article-title":"Targeted killing of TNFR2-expressing tumor cells and T(regs) by TNFR2 antagonistic antibodies in advanced S\u00e9zary syndrome","volume":"33","author":"Torrey","year":"2019","journal-title":"Leukemia"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.2641","article-title":"19-BI-1808-01, a phase 1\/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker\/depleter with or without pembrolizumab","volume":"42","author":"Rohrberg","year":"2024","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2007.07.011","article-title":"Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders","volume":"49","author":"Gambichler","year":"2008","journal-title":"J Dermatol Sci"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.196","article-title":"CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma","volume":"23","author":"Laharanne","year":"2010","journal-title":"Mod Pathol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdermsci.2025.04.010","article-title":"Overexpression of FOXM1 drives mycosis fungoides progression by regulating the cell cycle","volume":"118","author":"Liu","year":"2025","journal-title":"J Dermatol Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03889.x","article-title":"Decreased expression of Fas (APO-1\/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas","volume":"143","author":"Dereure","year":"2000","journal-title":"Br J Dermatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-109074","article-title":"Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression","volume":"111","author":"Contassot","year":"2008","journal-title":"Blood"},{"key":"B109","article-title":"Immunohistopathological study of c-FLIP protein in mycosis fungoides","volume":"18","author":"Rezk Hassan","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700868","article-title":"Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells","volume":"127","author":"Braun","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.376","article-title":"Reduction of Fas\/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma","volume":"147","author":"Wu","year":"2011","journal-title":"Arch Dermatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2756","article-title":"Analysis of the effect of Gentian Violet on apoptosis and proliferation in cutaneous T-cell lymphoma in an in vitro study","volume":"154","author":"Wu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001545","article-title":"Combined inhibition of Bcl-2 and NF\u03baB synergistically induces cell death in cutaneous T-cell lymphoma","volume":"134","author":"Froehlich","year":"2019","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/path.1341","article-title":"Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells","volume":"200","author":"Zhang","year":"2003","journal-title":"J Pathol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.9.2778","article-title":"Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells","volume":"98","author":"Qin","year":"2001","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-24-1020","article-title":"IL-9 promotes migratory dissemination of Malignant T cells by activating the HIF-1\u03b1-Cofilin-1 axis in cutaneous T-cell lymphoma","volume":"23","author":"Mukherjee","year":"2025","journal-title":"Mol Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/jco.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006440","article-title":"Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell Malignancies","volume":"7","author":"Miljkovic","year":"2023","journal-title":"Blood Adv"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/40166","article-title":"Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells","volume":"389","author":"Fuhlbrigge","year":"1997","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2007.00971.x","article-title":"Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates","volume":"35","author":"Magro","year":"2008","journal-title":"J Cutan Pathol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.jid.2022.06.016","article-title":"Cutaneous lymphocyte antigen is a potential therapeutic target in cutaneous T-cell lymphoma","volume":"142","author":"Peru","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/23495","article-title":"The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells","volume":"400","author":"Campbell","year":"1999","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0830","article-title":"Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-51","article-title":"Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study","volume":"30","author":"Yang","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.12.003","article-title":"CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation","volume":"74","author":"Hu","year":"2014","journal-title":"J Dermatol Sci"},{"key":"B130","doi-asserted-by":"publisher","first-page":"abstr 2514","DOI":"10.1200\/jco.2025.43.16_suppl.2514","article-title":"Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed\/refractory cutaneous T-cell lymphoma (R\/R CTCL)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/immu.200310025","article-title":"CCR8-dependent activation of the RAS\/MAPK pathway mediates anti-apoptotic activity of I-309\/ CCL1 and vMIP-I","volume":"33","author":"Louahed","year":"2003","journal-title":"Eur J Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.7.3465","article-title":"Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK\/ALP\/ILC)","volume":"164","author":"Homey","year":"2000","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41419-018-0267-9","article-title":"The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K\/Akt pathway activation","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20922","article-title":"CCR10 is expressed in cutaneous T-cell lymphoma","volume":"115","author":"Notohamiprodjo","year":"2005","journal-title":"Int J Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1492","article-title":"Skin homing of S\u00e9zary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV","volume":"107","author":"Narducci","year":"2006","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13054","article-title":"Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides","volume":"171","author":"Daggett","year":"2014","journal-title":"Br J Dermatol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jid.2020.06.034","article-title":"Cancer-associated fibroblasts in mycosis fungoides promote tumor cell migration and drug resistance through CXCL12\/CXCR4","volume":"141","author":"Aronovich","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2388567","article-title":"Investigational CXCR4 inhibitors in early phase development for the treatment of hematological Malignancies","volume":"33","author":"Martino","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-0610","article-title":"Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"14","author":"Chong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-3488","article-title":"TH2 cytokines from Malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-0532","article-title":"Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma","volume":"12","author":"Hahtola","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1516037","article-title":"IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model","volume":"60","author":"Wu","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.1111\/cup.14155","article-title":"Potential role of tumor-associated macrophages and CD163\/CD68 ratio in mycosis fungoides and S\u00e9zary syndrome in correlation with serum sCD163 and CCL22","volume":"49","author":"El-Guindy","year":"2022","journal-title":"J Cutaneous Pathol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.206","article-title":"Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo","volume":"134","author":"Wu","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014655","article-title":"Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed\/refractory cutaneous T-cell lymphoma","volume":"9","author":"Querfeld","year":"2025","journal-title":"Blood Adv"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jid.2019.11.018","article-title":"A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti-PD-1 in a murine model of cutaneous T-cell lymphoma (CTCL)","volume":"140","author":"Wu","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-29676-8_1218","article-title":"Clinical response to anti-CD47 immunotherapy is associated with rapid reduction of exhausted bystander CD4(+) BTLA(+) T cells in tumor microenvironment of mycosis fungoides","volume":"13","author":"Jiang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163518","article-title":"Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma","volume":"8","author":"Han","year":"2023","journal-title":"JCI Insight"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3008","article-title":"A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs","volume":"27","author":"Bagot","year":"2017","journal-title":"Eur J Dermatol"},{"key":"B151","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2133.2002.04994.x","article-title":"Dendritic cells and apoptosis in mycosis fungoides","volume":"147","author":"L\u00fcftl","year":"2002","journal-title":"Br J Dermatol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jaad.2009.06.082","article-title":"High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma","volume":"62","author":"Schlapbach","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.8.2929.h8002929_2929_2939","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-0171","article-title":"Extracorporeal photochemotherapy drives monocyte-to-dendritic cell maturation to induce anticancer immunity","volume":"78","author":"Ventura","year":"2018","journal-title":"Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1669015","article-title":"Extracorporeal photopheresis therapy rapidly changes the cytokine profile and tumor microenvironment in cutaneous T cell lymphoma","volume":"16","author":"Melchers","year":"2025","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12885-021-08142-7","article-title":"Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma","volume":"21","author":"Mehdi","year":"2021","journal-title":"BMC Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1474564","article-title":"The cancer-associated fibroblasts interact with Malignant T cells in mycosis fungoides and promote the disease progression","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: Malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12237","article-title":"Paucity of FOXP3+ cells in skin and peripheral blood distinguishes S\u00e9zary syndrome from other cutaneous T-cell lymphomas","volume":"20","author":"Klemke","year":"2006","journal-title":"Leukemia"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700371","article-title":"Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma","volume":"126","author":"Tiemessen","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404913","article-title":"FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival","volume":"21","author":"Gjerdrum","year":"2007","journal-title":"Leukemia"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094615","article-title":"IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity","volume":"110","author":"Litzinger","year":"2007","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ddg.15865","article-title":"Bacterial skin colonization and systemic antibiotic treatment in patients with cutaneous T-cell lymphoma","volume":"24","author":"Wang","year":"2026","journal-title":"J Dtsch Dermatol Ges"},{"key":"B165","doi-asserted-by":"crossref","DOI":"10.1111\/all.70292","article-title":"Staphylococcus aureus augments epithelial skin barrier damage through T cell activation in cutaneous T cell lymphoma","author":"Gluud","year":"2026","journal-title":"Allergy"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662353","article-title":"Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma","volume":"127","author":"Willerslev-Olsen","year":"2016","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/s0733-8635(15)00112-6","article-title":"Staphylococcus aureus induces signal transducer and activator of transcription 5\u2013dependent miR-155 expression in cutaneous T-cell lymphoma","volume":"141","author":"Willerslev-Olsen","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B168","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1641387","article-title":"Staphylococcal alpha-toxin tilts the balance between Malignant and non-malignant CD4(+) T cells in cutaneous T-cell lymphoma","volume":"8","author":"Bl\u00fcmel","year":"2019","journal-title":"Oncoimmunology"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and S\u00e9zary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-02015-7","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients","volume":"312","author":"Emge","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.0251","article-title":"Pembrolizumab in relapsed or refractory mycosis fungoides or S\u00e9zary syndrome","volume":"161","author":"Elghawy","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115484","article-title":"Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed\/refractory IIB\/IVB mycosis fungoides\/S\u00e9zary syndrome patients after previous systemic treatment. EORTC-1652-CLTG \u201cPARCT","volume":"222","author":"Stadler","year":"2025","journal-title":"Eur J Cancer"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.03.287","article-title":"Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment","volume":"8","author":"Gao","year":"2023","journal-title":"JCI Insight"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000468","article-title":"Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202502206","article-title":"CD47 inhibits phagocytosis through Vav dephosphorylation","volume":"224","author":"Miller","year":"2025","journal-title":"J Cell Biol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00271-4","article-title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome: a multicentre, phase 1 study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Lancet Haematology"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2026.153330","article-title":"Clinical advances in CD47-SIRP\u03b1 axis-targeted cancer immunotherapy: mechanisms, strategies, challenges, and future perspectives","volume":"802","author":"Li","year":"2026","journal-title":"Biochem Biophys Res Commun"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548292","article-title":"ADCC: the rock band led by therapeutic antibodies, tumor and immune cells","volume":"16","author":"Vincken","year":"2025","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2024.113715","article-title":"A real-time antibody-dependent cellular phagocytosis assay by live cell imaging","volume":"531","author":"Shi","year":"2024","journal-title":"J Immunol Methods"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010141","article-title":"Mogamulizumab combined with extracorporeal photopheresis as a novel therapy in erythrodermic cutaneous T-cell lymphoma","volume":"16","author":"Ninosu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70078","article-title":"CD16A shedding regulates innate cell engager-induced serial killing by natural killer cells","volume":"55","author":"Zambarda","year":"2025","journal-title":"Eur J Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.4.1429","article-title":"MHC class I expression on tumor targets inhibits natural killer cell-mediated cytotoxicity without interfering with target recognition","volume":"150","author":"\u00f6Kaufman","year":"1993","journal-title":"J Immunol"},{"key":"B187","doi-asserted-by":"crossref","DOI":"10.1111\/imr.13394","article-title":"Enhancing Fc-mediated effector functions of monoclonal antibodies: the example of HexaBodies","volume":"328","author":"van der Horst","year":"2024","journal-title":"Immunol Rev"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.11.009","article-title":"Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity","volume":"26","author":"van Hauten","year":"2024","journal-title":"Cytotherapy"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2026.102140","article-title":"Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell Malignancies","volume":"28","author":"Ruppel","year":"2026","journal-title":"Cytotherapy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1899436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:48Z","timestamp":1784699568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1899436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":189,"alternative-id":["10.3389\/fimmu.2026.1899436"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1899436","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1899436"}}